Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Illumina's (NASDAQ: ILMN) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Canaccord Genuity analyst Kyle Mikson CFA has maintained their neutral stance on ILMN stock, giving a Hold rating today. Geoff Meacham has given his Hold rating due to a combination of factors ...

On Feb 16, we issued an updated research report on Illumina, Inc. ILMN. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers.

The "Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type, Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology ...

The mission of the Integrated Genomics Shared Resource (SR) is to deliver a comprehensive spectrum of genomic and functional genomic technologies and bioinformatic services to cancer center members ...

For most researchers DNA microarrays are synonymous with high-throughput gene expression analysis. But they also are invaluable genotyping tools. Now that the International HapMap Project (see article ...

Illumina's (ILMN-5.63%) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...